treprostinil sodium: Pharmaceutical manufacturers, suppliers, and wholesalers

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Liquidia Tech	YUTREPIA	treprostinil sodium	POWDER;INHALATION	213005	NDA	Liquidia Technologies, Inc.	72964-011-01	7 BLISTER PACK in 1 CARTON (72964-011-01) / 4 CAPSULE in 1 BLISTER PACK / 1 CAPSULE in 1 CAPSULE	2025-05-23
Liquidia Tech	YUTREPIA	treprostinil sodium	POWDER;INHALATION	213005	NDA	Liquidia Technologies, Inc.	72964-012-01	7 BLISTER PACK in 1 CARTON (72964-012-01) / 4 CAPSULE in 1 BLISTER PACK / 1 CAPSULE in 1 CAPSULE	2025-05-23
Liquidia Tech	YUTREPIA	treprostinil sodium	POWDER;INHALATION	213005	NDA	Liquidia Technologies, Inc.	72964-013-01	7 BLISTER PACK in 1 CARTON (72964-013-01) / 4 CAPSULE in 1 BLISTER PACK / 1 CAPSULE in 1 CAPSULE	2025-05-23
Liquidia Tech	YUTREPIA	treprostinil sodium	POWDER;INHALATION	213005	NDA	Liquidia Technologies, Inc.	72964-014-01	7 BLISTER PACK in 1 CARTON (72964-014-01) / 4 CAPSULE in 1 BLISTER PACK / 1 CAPSULE in 1 CAPSULE	2025-05-23
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: May 26, 2026

Treprostinil Sodium suppliers: which companies sell the drug substance and finished product (US and key markets)

Treprostinil sodium is supplied through a small set of global manufacturers and contract manufacturers, with product availability in the US tied to specific finished-dose platforms (injection and inhalation) and to the ability to source compliant treprostinil sodium API and excipients at scale. The practical supplier map is split by (1) API/active ingredient sourcing and (2) finished-dose manufacturing and distribution for the approved treprostinil sodium products.

Key supplier reality for procurement and partnering: finished treprostinil sodium supply is constrained by the number of approved product manufacturing sites and quality systems supporting commercial lots, not by the number of potential API producers. API procurement is still a bottleneck when API and key excipients have limited qualified supply chains.

Who supplies treprostinil sodium injection and treprostinil sodium inhalation in the US?

US approved product supply (brand platforms)

In the US, treprostinil sodium is marketed in two major commercially relevant delivery platforms:

Treprostinil sodium injection (parenteral; including continuous infusion)
Treprostinil sodium inhalation solution (for inhaled dosing)

Commercial supply is dominated by the companies holding the reference product manufacturing/marketing rights and their contract manufacturing network for the approved presentations.

Practical supplier categories

Finished-product supplier (marketing authorization holder for each approved NDA/BLA label)
Contract manufacturer (site that makes filled drug product under cGMP for the label holder)
Distributor network (wholesalers and specialty pharmacy fulfillment)

Procurement implications

If you are buying finished product, “supplier” means the label holder and their appointed distributors, not just API producers.
If you are buying API, suppliers are identified by DMF/API qualification status and compatibility with finished product formulation and stability requirements.

Which companies manufacture treprostinil sodium API (drug substance) for finished-dose producers?

Treprostinil sodium API supply chain structure

Treprostinil sodium API is manufactured by specialized chemical API makers with:

cGMP compliance and validated impurity profiles
ability to supply consistent particle size, polymorphic form, and water content targets
documentation support (DMF/letter of authorization where applicable)

How to map API suppliers correctly

A defensible supplier shortlist requires triangulation from:

FDA Drug Master Files (DMFs) or letters of authorization tied to approved products
commercial availability through established chemical distributors
customer qualification data (CoA consistency, impurity levels, extractables/leachables compatibility with finished product packaging)

This supplier map is materially different from the finished-dose market map.

What is the Orange Book status of treprostinil sodium products, and does it affect supplier entry?

Orange Book linkage to supplier access

Orange Book listing drives:

which generic products can be approved
which ANDAs are pending
which Paragraph IV pathways can create supply and licensing events

For procurement and supplier risk control, the most important Orange Book items are:

active ingredients and dosage forms covered
patents listed by the NDA holder
any expiration dates and exclusivity restraints that block generic manufacturing sites from competing

Supplier risk

Even when API is available, finished-product entry can be blocked by:

patent thickets on formulation or method-of-use
manufacturing know-how for stable treprostinil sodium dosing platforms
device and delivery system constraints (especially for inhalation)

When do treprostinil sodium products lose exclusivity and what does that mean for suppliers?

Timeline drivers

Exclusivity and patent term are the main timeline drivers for:

additional finished-product entrants
increased distributor competition
contract manufacturing reallocations to more than one supplier

Commercial effect

Once exclusivity/patent barriers fall, the typical supplier outcomes include:

more ANDA-labeled suppliers for the same presentation
price pressure at the wholesaler and specialty pharmacy level
greater contract manufacturing competition for the bottle/vial formats and inhalation solution lines

What formulations are protected for treprostinil sodium, and who supplies that dosage form?

Formulation differentiation

Treprostinil sodium supply is shaped by differences in:

pH and buffering system targets
solubilizers and excipients used to meet inhalation or injection stability
container closure system and extractables/leachables controls

Why formulation protection matters to suppliers

Even if API exists, a supplier must:

meet approved formulation specs for the label
validate the finished dose and packaging
pass stability and compatibility demands tied to the specific presentation

That ties supplier eligibility to product-level development and quality systems.

How many suppliers can qualify treprostinil sodium inhalation solution vs injection?

Inhalation solution supplier constraints

Inhalation solution adds constraints absent from injection:

aerosol delivery performance requirements
packaging and nebulization compatibility
moisture and stability windows
batch-to-batch viscosity and particle specification controls (where applicable)

Injection supplier constraints

Injection supply constraints focus on:

sterile manufacturing lines
continuous infusion compatibility
container closure integrity and chemical stability across infusion settings

In practice, inhalation solution typically has fewer qualified supply options than injection due to the tighter integration of solution, device pathway, and stability requirements.

Which contract manufacturers support treprostinil sodium finished drug product?

Contract manufacturing categories

For treprostinil sodium finished products, contract manufacturing typically falls into:

sterile fill-finish for injections
sterile manufacturing for inhalation solution (site-dependent)
packaging and labeling
quality control labs and release testing partnerships

How to operationalize this

A credible contract manufacturer shortlist is built from:

publicly listed manufacturing site information for the approved products
inspection history patterns and quality compliance signals
supply continuity and lot availability at commercial scale

Which companies challenge treprostinil sodium with generics or biosimilar-like pathways?

Treprostinil sodium is a small-molecule drug substance. The competitive entry risk is primarily from:

ANDA generic versions
505(b)(2) reformulations or new presentation routes
possible 4b/4c pathways that change formulation or device integration

Supplier risk is highest where generic applicants target the same dosage forms and seek to replace the label holder’s finished supply.

What generic entry risks exist for treprostinil sodium injection or inhalation?

Manufacturing/IP barriers

Generic entry risk depends on:

patent coverage on formulations, stability, or method-of-use
reliance on specific excipient systems
ability to reproduce sterile and packaging controls at scale

Supply-chain barriers

Even if legal entry is possible, the practical barriers include:

qualified sterilization and aseptic processing capacity
validated analytical methods and impurity control
stable procurement of API and excipients under cGMP controls

How do treprostinil sodium supplier deals and licensing typically work?

Common structures

Licensing and supply deals around treprostinil sodium usually follow:

API supply agreements paired with formulation know-how
contract manufacturing arrangements under quality agreements
distribution and specialty pharmacy agreements for launch and steady-state supply

Why deal structure matters

The “supplier” you end up with is often determined by:

who holds regulatory/quality knowledge for the approved formulation and presentation
who can produce commercial lots under the label holder’s quality system
who can secure continuous supply of API through validated suppliers

Geographic coverage: which supplier options exist outside the US?

Typical international patterns

International treprostinil sodium supply is shaped by:

regional marketing authorization holders
local importation and distribution networks
GMP release testing requirements by region

Most procurement strategies need a “two-map” approach:

map finished-product availability in the target region
map API availability and qualification status that can support any local manufacturing or repackaging

Key Takeaways

Treprostinil sodium supply is best managed by separating API suppliers from finished-dose suppliers because finished-product qualification and distribution capacity dominate real-world availability.
Supplier entry is constrained by approved presentation manufacturing, sterile and stability requirements, and packaging/device compatibility for inhalation.
Exclusivity and patent coverage in the Orange Book shape when additional finished-dose suppliers can realistically supply the market.
Supplier due diligence should prioritize cGMP readiness, DMF/authorization linkage, and history of commercial lot release, not only theoretical API availability.

FAQs

Which distributors typically supply treprostinil sodium finished product to hospitals in the US?

Specialty-focused wholesalers and direct-to-provider distribution channels supply treprostinil sodium through the label holder’s commercial network and specialty pharmacy workflows.

Can a treprostinil sodium API supplier also supply the finished injection or inhalation solution?

Only if they have (or contract for) the required cGMP sterile manufacturing, approved formulation capability, and packaging controls for the specific approved presentation.

What quality documents matter most when qualifying treprostinil sodium API suppliers?

CoA/impurity profiles, specification ranges, stability data, change-control history, and regulatory documentation linkage (DMF/authorization) tied to approved use.

How does inhalation solution packaging affect treprostinil sodium supply qualification?

Packaging and closure system compatibility can materially affect stability and deliverability, so supplier qualification must be presentation-specific, not generic.

What is the fastest path to additional treprostinil sodium supply if demand increases?

Expanding capacity through additional sterile fill-finish/finished-dose contract manufacturers for the approved presentation is typically faster than new API qualification alone.

References

No sources were provided in the prompt.